Some three years after the University of Pennsylvania claimed four of Roche’s breast cancer meds infringed its intellectual ...

As a line extension, it expands the blockbuster drug franchise and extends the patent protection for Herceptin—a strategy Roche could apply to other biologics as well. “When we looked at the ...

The battle of wills between Roche and NICE over the breast cancer drug Kadcyla has entered a new phase – and one that could have an impact for the whole UK industry. Yesterday saw Roche mount ...

It is hoped that by coupling trastuzumab (Herceptin; Genentech/Roche) — a humanized monoclonal antibody (mAb) specific for the human epidermal growth factor receptor 2 (HER2; also known as ERBB2 ...

Roche's Herceptin is a humanised monoclonal antibody designed to target and block the function of HER2, a protein produced by a specific gene with cancer-causing potential when it is overexpressed.

HER2 (also known as ERBB2) is a key oncogene in breast cancer and is found in 2–4% of patients with non-small-cell lung cancer (NSCLC), typically in female individuals, who are non-smokers, and have ...

However, Roche faced a CHF 1bn sales decline from the loss of exclusivity on older products, including cancer therapies Avastin (bevacizumab), Herceptin (trastuzumab), and Rituxan (rituximab).

Roche and its Genentech subsidiary are planning to hitch up their cardiovascular, renal and metabolism R&D work and shift it over to a new center in Harvard’s Enterprise Research Campus. | Roche and ...

Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).

Key HER2+ Gastric Cancer companies in the market include - Roche, Elevar Therapeutic, Bristol-Myers Squibb, Merck, Daiichi ...